Key result
Targeting the endothelin system emerges as a potential precision medicine strategy in HFpEF.
Why the study?
The role of targeting the endothelin system as a precision medicine approach in heart failure with preserved ejection fraction is examined.
## Authors - Torbjørn Omland (University of Oslo): h-index 68; 29,418 citations; corresponding author ## Topics - Pulmonary Hypertension Research and Treatments - Cardiovascular Issues in Pregnancy - Cardiovascular Function and Risk Factors ## References - Robert J Cody, Garrie J. Haas, Philip F. Binkley, Quinn Capers, R Kelley. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85(2):504-509. doi:10.1161/01.cir.85.2.504. - Stephan Dorfs, Wolfgang Zeh, Willibald Hochholzer, Nikolaus Jander, Rolf-Peter Kienzle, Burkert Mathias Pieske, et al. Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. European Heart Journal. 2014;35(44):3103-3112. doi:10.1093/eurheartj/ehu315. - T. M. Omland, Rolv Terje Lie, A. Aakvaag, Torbørn Aarsland, Kenneth Dickstein. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 1994;89(4):1573-1579. doi:10.1161/01.cir.89.4.1573. - Nazzareno Galiè, Marc J.C. Humbert, Jean‐Luc Vachiéry, Simon Gibbs, Irene Marthe Lang, Adam Torbicki, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2015;37(1):67-119. doi:10.1093/eurheartj/ehv317. - Adel Giaid, Masashi Yanagisawa, David Langleben, René P. Michel, Robert D. Levy, Hani Shennib, et al. Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension. New England Journal of Medicine. 1993;328(24):1732-1739. doi:10.1056/nejm199306173282402. - Matthew D. Jankowich, Wen‐Chih Wu, Gaurav Choudhary. Association of Elevated Plasma Endothelin-1 Levels With Pulmonary Hypertension, Mortality, and Heart Failure in African American Individuals. JAMA Cardiology. 2016;1(4):461. doi:10.1001/jamacardio.2016.0962. - B. Koller, Regina Steringer‐Mascherbauer, Christian Ebner, Th. Weber, Marcus Ammer, Jörg Eichinger, et al. Pilot Study of Endothelin Receptor Blockade in Heart Failure with Diastolic Dysfunction and Pulmonary Hypertension (BADDHY-Trial). Heart Lung and Circulation. 2016;26(5):433-441. doi:10.1016/j.hlc.2016.09.004. - María Valero‐Muñoz, Shanpeng J. Li, Richard M. Wilson, Batbold Boldbaatar, Marc Iglarz, Flora Sam. Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction. Circulation Heart Failure. 2016;9(11). doi:10.1161/circheartfailure.116.003381. - Ahmed U. Fayyaz, William D. Edwards, Joseph John Maleszewski, Ewa A. Konik, Hilary M. DuBrock, Barry A. Borlaug, et al. Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. Circulation. 2017;137(17):1796-1810. doi:10.1161/circulationaha.117.031608. - Masaru Obokata, Thomas Patrick Olson, Yogesh N.V. Reddy, Vojtěch Melenovský, Garvan C. Kane, Barry A. Borlaug. Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction. European Heart Journal. 2018;39(30):2810-2821. doi:10.1093/eurheartj/ehy268. - Carolyn S.P. Lam, Adriaan A. Voors, Rudolf A. de Boer, Scott David Solomon, Dirk Jan van Veldhuisen. Heart failure with preserved ejection fraction: from mechanisms to therapies. European Heart Journal. 2018;39(30):2780-2792. doi:10.1093/eurheartj/ehy301. - Masaru Obokata, Yogesh N.V. Reddy, Vojtěch Melenovský, Garvan C. Kane, Thomas Patrick Olson, Petr Jarolı́m, et al. Myocardial Injury and Cardiac Reserve in Patients With Heart Failure and Preserved Ejection Fraction. Journal of the American College of Cardiology. 2018;72(1):29-40. doi:10.1016/j.jacc.2018.04.039. - Adriaan A. Voors, Daan Kremer, Christopher Geven, Jozine M. ter Maaten, Joachim Struck, Andreas Bergmann, et al. Adrenomedullin in Heart Failure: Pathophysiology and Therapeutic Application. European Journal of Heart Failure. 2018;21(2):163-171. doi:10.1002/ejhf.1366. - Masaru Obokata, Barry A. Borlaug. Left Atrial Dysfunction: The Next Key Target in Heart Failure with Preserved Ejection Fraction. European Journal of Heart Failure. 2019;21(4):506-508. doi:10.1002/ejhf.1420. - Masaru Obokata, Garvan C. Kane, Yogesh N.V. Reddy, Vojtěch Melenovský, Thomas Patrick Olson, Petr Jarolı́m, et al. The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction. European Heart Journal. 2019;40(45):3707-3717. doi:10.1093/eurheartj/ehz626. - Anthony P. Davenport, Kelly A. Hyndman, Neeraj Dhaun, Christopher Southan, Donald E. Kohan, Jennifer S. Pollock, et al. Endothelin. Pharmacological Reviews. 2016;68(2):357-418. doi:10.1124/pr.115.011833.
No takes yet. Share an insight, caveat, or question.
Torbjørn Omland (2019) conducted an editorial in Heart failure with preserved ejection fraction. Targeting the endothelin system was evaluated. Targeting the endothelin system is discussed as a potential precision medicine approach in heart failure with preserved ejection fraction, though no clinical trial data are reported in the abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: